#64 Evolution of Treatment Paradigms in ANCA Vasculitis, with David Jayne
A pinch of salt - A podcast by ERAShow Notes
Join A pinch of salt, as we sit down with David Jayne to trace the rapid transformation of ANCA-associated vasculitis care. From the historic cyclophosphamide–glucocorticoid backbone to biologics like rituximab and newer targeted strategies such as complement inhibition (including avacopan), this episode unpacks how clinicians can balance efficacy, safety, and quality of life—while looking ahead to what may define the next decade of treatment.
More from A pinch of salt - A podcast by ERA
For decades, “volume status” meant a (un)healthy dose of educated guessing. What if you could just look? Faeq Husain-Syed (Giessen) joins "A pinch of salt" to explain how kidney venous Doppler makes congestion visible, and whether Point-of-care Ultrasound is ready for prime time.
Heart over there, kidney over here, metabolism somebody else’s problem? Not anymore. Amaryllis Van Craenenbroeck (KU Leuven) makes the case for Cardiovascular-Kidney-Metabolic syndrome as one continuum, not three separated clinics. Four drug classes, three organs, one patient, prevention upstream, and a fair hearing for the sceptics who call it disease-mongering.
We watch creatinine rise and fall all the time, but a failing kidney allograft is more than a numbers game. Annelies de Weerd (Erasmus MC Rotterdam) covers when to call it failure, the immunosuppression taper, and helping patients through what feels like a step backwards.
Every nephrology trainee in Europe has heard about it, stressed about it, or is quietly pretending it doesn’t exist: the ESENeph. Is it a genuine European passport, or just one more exam? Hugo Diniz talks to David Lappin, about the exam’s format, its career value, and why trainees should sign up.